Cargando…

Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients

INTRODUCTION: Breakthrough COVID-19 may occur in vaccinated people, and may result from declining vaccine effectiveness or highly transmittable SARS-CoV-2 variants, such as the B.167.2 (delta) variant. We investigated risk factors and outcomes for infection with the delta variant among vaccinated he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wand, Ori, Nacasch, Naomi, Fadeela, Ayman, Shashar, Moshe, Grupper, Ayelet, Benchetrit, Sydney, Erez, Daniel, Shitrit, Pnina, Cohen-Hagai, Keren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852959/ https://www.ncbi.nlm.nih.gov/pubmed/35175577 http://dx.doi.org/10.1007/s40620-022-01245-9

Ejemplares similares

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Humoral Response to Hepatitis B and COVID-19 Vaccine among Maintenance Hemodialysis Patients
por: Nacasch, Naomi, et al.
Publicado: (2022)

Kinetics of the humoral response 1-year following vaccination with BNT162b2 SARS-CoV-2 vaccine among maintenance hemodialysis patients
por: Wand, Ori, et al.
Publicado: (2022)

Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients
por: Einbinder, Yael, et al.
Publicado: (2022)

Outcomes From Infections With Variant Strains of SARS-CoV-2 Among Patients Receiving Maintenance Hemodialysis
por: Wand, Ori, et al.
Publicado: (2021)

Long-term Antibody Response to the BNT162b2 Vaccine Among Maintenance Hemodialysis Patients
por: Nacasch, Naomi, et al.
Publicado: (2022)

The Clinical Significance of LDL-Cholesterol on the Outcomes of Hemodialysis Patients with Acute Coronary Syndrome
por: Cohen-Hagai, Keren, et al.
Publicado: (2023)

WORSE OUTCOMES OF VARIANT COVID-19 VIRUSES IN CHRONIC HEMODYALISYS PATIENTS
por: WAND, ORI, et al.
Publicado: (2021)

Intra-Cranial Arterial Calcifications in Hemodialysis Patients
por: Fanadka, Feda, et al.
Publicado: (2023)

Intracranial and heart valve calcifications in hemodialysis patients—Interrelationship and clinical impact
por: Fanadka, Feda, et al.
Publicado: (2022)

Disease severity and renal outcomes of patients with chronic kidney disease infected with COVID-19
por: Gur, Efrat, et al.
Publicado: (2022)

Mortality prediction using a modified R(2)CHA(2)DS(2)-VASc score among hospitalized COVID-19 patients
por: Levy, David, et al.
Publicado: (2022)

Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland
por: Rzymski, Piotr, et al.
Publicado: (2022)

Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
por: Wang, Stephen Y, et al.
Publicado: (2022)

Genetic emergence of B.1.617.2 in COVID-19
por: Kirola, L.
Publicado: (2021)

Presence of Sarcopenia before Kidney Transplantation Is Associated with Poor Outcomes
por: Druckmann, Ido, et al.
Publicado: (2022)

Hemodialysis Serum Stimulates the TXNIP-eNOS-STAT3 Inflammatory Pathway In Vitro
por: Cohen-Hagai, Keren, et al.
Publicado: (2023)

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge
por: Bierle, Dennis M., et al.
Publicado: (2021)

Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
por: Connor, Bradley A, et al.
Publicado: (2021)

Analysis of the Delta Variant B.1.617.2 COVID-19
por: Shiehzadegan, Shayan, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease before Kidney Transplantation Correlates with New Onset Diabetes and Poor Metabolic Outcomes
por: Grupper, Ayelet, et al.
Publicado: (2022)

Effect of aspirin on primary prevention of cardiovascular disease and mortality among patients with chronic kidney disease
por: Haim-Pinhas, Hadar, et al.
Publicado: (2022)

Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2022)

Vaccine effectiveness against the B.1.617.2 in the intensive care unit
por: Koc, Ibrahim, et al.
Publicado: (2023)

Genome Sequences of the Delta Variant (B.1.617.2) and the Kappa Variant (B.1.617.1) Detected in Morocco
por: Melloul, Marouane, et al.
Publicado: (2021)

The efficacy of COVID-19 vaccines against the B.1.617.2 (delta) variant
por: Cai, Changjing, et al.
Publicado: (2021)

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
por: Lopez Bernal, Jamie, et al.
Publicado: (2021)

Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers
por: Kemp, Steven A., et al.
Publicado: (2022)

Effect of Vitamin D Status on Von Willebrand Factor and ADAMTS13 in Diabetic Patients on Chronic Hemodialysis
por: Cohen-Hagai, Keren, et al.
Publicado: (2017)

Increasing severity of COVID-19 in pregnancy with Delta (B.1.617.2) variant surge
por: Adhikari, Emily H., et al.
Publicado: (2022)

Serial intervals in SARS-CoV-2 B.1.617.2 variant cases
por: Pung, Rachael, et al.
Publicado: (2021)

Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
por: Arora, Prerna, et al.
Publicado: (2021)

Structural Evolution of Delta (B.1.617.2) and Omicron (BA.1) Spike Glycoproteins
por: Prandi, Ingrid Guarnetti, et al.
Publicado: (2022)

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
por: Mlcochova, Petra, et al.
Publicado: (2021)

Chest CT features of children infected by B.1.617.2 (Delta) variant of COVID-19
por: Cheng, Qi-Rui, et al.
Publicado: (2021)

Codon usage divergence in Delta variants (B.1.617.2) of SARS-CoV-2
por: Li, Gun, et al.
Publicado: (2022)

Age-Varying Susceptibility to the Delta Variant (B.1.617.2) of SARS-CoV-2
por: Chun, June Young, et al.
Publicado: (2022)

Charge transport properties of SARS-CoV-2 Delta variant (B.1.617.2)
por: He, Lijun, et al.
Publicado: (2022)

Enhanced fitness of SARS-CoV-2 B.1.617.2 Delta variant in ferrets
por: Sun, Xiangjie, et al.
Publicado: (2023)

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
por: Seppälä, Elina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k0cjn6heod66al2qqk47keic9f